Last reviewed · How we verify

NCT06016595

Chronic Prostatitis/Chronic Pelvic Pain Syndrome Patients

Completed Last updated 29 August 2023
What this trial tests

trial testing Chronic prostatitis/chronic pelvic pain syndrome in Chronic Prostatitis With Chronic Pelvic Pain Syndrome in 112 participants. Completed in 10 May 2023.

Timeline
1 January 2020
Primary endpoint
31 December 2022
10 May 2023

Quick facts

Lead sponsorHisar Intercontinental Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment112
Start date1 January 2020
Primary completion31 December 2022
Estimated completion10 May 2023
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Hisar Intercontinental Hospital

Who can join

Adults 20 to 60, male only, with Chronic Prostatitis With Chronic Pelvic Pain Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Chronic prostatitis/chronic pelvic pain syndrome (CPPS) is a common health problem among men and can cause severe quality of life. The pathophysiology of CPPS is still poorly understood and effective treatments are a challenging issue. This study aims to investigate the possible relationship between the presence of microorganisms in the prostatic fluid and symptom severity by presenting a retrospective analysis based on data from CPPS patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Chronic Prostatitis With Chronic Pelvic Pain Syndrome

Currently open trials in the same condition.

Other Hisar Intercontinental Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06016595.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing